Figure 3

Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice. Ha-ras transgenic mice with established superficial bladder cancer were randomized to receive either belinostat dissolved in L-Arginine (100 mg/kg, IP, qd, 5 days on, 2 days off, 3 cycles) or L-Arginine alone as a control following the same dose scheduling. All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-ras transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. A, Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). B, Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).